Head-to-head evidence
BCMA CAR-NK (Shenzhen Pregene Biopharma) vs IM21 CAR-T cells
Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.
Multiple Myeloma
Shared mechanism: BCMA · full Multiple Myeloma pipeline
BCMA CAR-NK (Shenzhen Pregene Biopharma)
Developed by Shenzhen Pregene Biopharma Co., Ltd.
NCT05652530 · Phase 1 · status unknown
This was an open-label, single-arm study with no randomization, no blinding, and no comparator arm, in only 19 participants, and it measured only safety. Results have not been posted yet.
IM21 CAR-T cells
Developed by Beijing Immunochina Medical Science & Technology Co., Ltd.
NCT03711864 · Phase 1 · status unknown
This is a small, unblinded, single-arm safety study with no comparison group, and no results have been posted yet.
The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: BCMA CAR-NK (Shenzhen Pregene Biopharma)'s landscape · IM21 CAR-T cells's landscape